1H magnetic resonance spectroscopy findings in idiopathic inflammatory myopathies at 3 T: Feasibility and first results

Investigative Radiology

Volumn 48, Issue 7, 2013, Pages 509-516

  Subhawong, Ty K ^a   Wang, Xin ^b   MacHado, Antonio J ^b   Mammen, Andrew L ^c,d   Christopher Stine, Lisa ^c,d   Barker, Peter B ^b   Carrino, John A ^b   Fayad, Laura M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c Division of Rheumatology   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; LIPID; TRIMETHYLAMINE; BIOLOGICAL MARKER; CREATININE; METHYLAMINE; PROTON; DIAGNOSTIC AGENT;

ADULT; AGED; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MYOSITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; DIAGNOSTIC USE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION; ARTICLE; METHODOLOGY;

BIOLOGICAL MARKERS; CREATININE; FEASIBILITY STUDIES; FEMALE; HUMANS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METHYLAMINES; MYOSITIS; PILOT PROJECTS; PROTONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 84879938720     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3182823562     Document Type: Review

References (33)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325:1487-1498.
2. Christopher-Stine L, Plotz PH. Adult inflammatory myopathies. Best Pract Res Clin Rheumatol. 2004;18:331-344. (Pubitemid 38950056)
3. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362: 971Y982.
4. Kuo GP, Carrino JA. Skeletal muscle imaging and inflammatory myopathies. Curr Opin Rheumatol. 2007;19:530-535. (Pubitemid 47530871)
5. Cox FM, Reijnierse M, van Rijswijk CSP, et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford). 2011;50:1153-1161.
6. Walker UA. Imaging tools for the clinical assessment of idiopathic inflammatory myositis. Curr Opin Rheumatol. 2008;20:656-661.
7. Schweitzer ME, Fort J. Cost-effectiveness of MR imaging in evaluating polymyositis. AJR Am J Roentgenol. 1995;165:1469-1471.
8. Fayad LM,Wang X, Salibi N, et al. A feasibility study of quantitative molecular characterization of musculoskeletal lesions by proton MR spectroscopy at 3 T. AJR Am J Roentgenol. 2010;195:W69YW75.
9. Fayad LM, Barker PB, Jacobs MA, et al. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. AJR Am J Roentgenol. 2007;188: 1513Y1520.
10. Wang C-K, Li C-W, Hsieh T-J, et al. Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: initial results. Radiology. 2004;232:599-605. (Pubitemid 38971305)
11. Fayad LM, Bluemke DA, McCarthy EF, et al. Musculoskeletal tumors: use of proton MR spectroscopic imaging for characterization. J Magn Reson Imaging. 2006;23:23-28. (Pubitemid 43100714)
12. Fayad LM, Barker PB, Bluemke DA. Molecular characterization of musculoskeletal tumors by proton MR spectroscopy. Semin Musculoskelet Radiol. 2007;11:240-245. (Pubitemid 351272526)
13. Subhawong TK, Wang X, Durand DJ, et al. Proton MR spectroscopy in metabolic assessment of musculoskeletal lesions. AJR Am J Roentgenol. 2012;198: 162Y172.
14. Chung YL, Smith EC, Williams SC, et al. In vivo proton magnetic resonance spectroscopy in polymyositis and dermatomyositis: a preliminary study. Eur J Med Res. 1997;2:483-487.
15. Dion E, Cherin P, Payan C, et al. Magnetic resonance imaging criteria for distinguishing between inclusion body myositis and polymyositis. J Rheumatol. 2002;29:1897-1906. (Pubitemid 34988698)
16. Natt O, Bezkorovaynyy V, Michaelis T, et al. Use of phased array coils for a determination of absolute metabolite concentrations. Magn Reson Med. 2005; 53:3-8. (Pubitemid 40110470)
17. Wang X, Fayad LM, Barker PB. Quantitative Musculoskeletal MRS Using the Phantom Replacement Method and Phased-Array Receiver Coils. Presented at: International Society for Magnetic Resonance in Medicine, Montréal, Québec, Canada; May 2011.
18. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129:35-43. (Pubitemid 127454051)
19. Naressi A, Couturier C, Castang I, et al. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med. 2001;31:269-286. (Pubitemid 32378728)
20. Fayad LM, Salibi N, Wang X, et al. Quantification of muscle choline concentrations by proton MR spectroscopy at 3 T: technical feasibility. AJR Am J Roentgenol. 2010;194:W73YW79.
21. Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep. 2001;3:334-345.
22. Park JH, Vansant JP, Kumar NG, et al. Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease. Radiology. 1990;177:473.
23. Newman ED, Kurland RJ. P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis. Altered energy utilization during exercise. Arthritis Rheum. 1992;35:199-203.
24. Torriani M, Thomas BJ, Halpern EF, et al. Intramyocellular lipid quantification: repeatability with 1H MR spectroscopy. Radiology. 2005;236:609-614. (Pubitemid 41023447)
25. Torriani M. Measuring muscle lipids with 1H-MR spectroscopy. Skeletal Radiol. 2007;36:607-608. (Pubitemid 46864001)
26. Mengiardi B, Schmid MR, Boos N, et al. Fat content of lumbar paraspinal muscles in patients with chronic low back pain and in asymptomatic volunteers: quantification with MR spectroscopy. Radiology. 2006;240:786-792. (Pubitemid 44267336)
27. Pfirrmann CWA, Schmid MR, Zanetti M, et al. Assessment of fat content in supraspinatus muscle with proton MR spectroscopy in asymptomatic volunteers and patients with supraspinatus tendon lesions. Radiology. 2004;232:709-715. (Pubitemid 39100252)
28. Bottomley PA, Lee Y, Weiss RG. Total creatine in muscle: imaging and quantification with proton MR spectroscopy. Radiology. 1997;204:403-410. (Pubitemid 27337486)
29. Nakae I, Mitsunami K, Omura T, et al. Proton magnetic resonance spectroscopy can detect creatine depletion associated with the progression of heart failure in cardiomyopathy. J Am Coll Cardiol. 2003;42:1587-1593. (Pubitemid 37378437)
30. vKreis R, JungB, Slotboom J, et al. Effect of exercise on the creatine resonances in 1H MR spectra of human skeletal muscle. J Magn Reson. 1999;137:350-357. (Pubitemid 129608263)
31. Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. 2011;CD004760.
32. Vermathen P, Boesch C, Kreis R. Mapping fiber orientation in human muscle by proton MR spectroscopic imaging. Magn Reson Med. 2003;49:424-432. (Pubitemid 36262809)
33. Gao F, Bottomley PA, Arnold C, et al. The effect of orientation on quantification of muscle creatine by 1H MR spectroscopy. Magn Reson Imaging. 2003;21:561-566. (Pubitemid 36899090) Young Investigator's